Biogen Company Profile (NASDAQ:BIIB)

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

Biogen Inc. (NASDAQ:BIIB) posted its quarterly earnings data on Tuesday, April, 25th. The company reported $5.20 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $4.97 by $0.23. The business earned $2.81 billion during the quarter, compared to the consensus estimate of $2.73 billion. Biogen had a net margin of 30.17% and a return on equity of 38.17%. The business's revenue for the quarter was up 3.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $4.79 earnings per share. View Biogen's Earnings History.

Biogen is scheduled to release their next quarterly earnings announcement on Tuesday, July, 25th 2017. View Earnings Estimates for Biogen.

24 brokerages have issued 12-month target prices for Biogen's shares. Their predictions range from $271.00 to $442.00. On average, they expect Biogen's stock price to reach $327.76 in the next year. View Analyst Ratings for Biogen.

Here are some recent quotes from research analysts about Biogen stock:

• 1. Cantor Fitzgerald analysts commented, "A German patient treated for three years with Tysabri and then with a single dose of Ocrevus developed PML." (5/25/2017)
• 2. Cowen and Company analysts commented, "Biogen reported Q1 revenues of $2.81B (+3% Y/Y, vs. consensus of $2.74B) and non-." (4/25/2017)
• 3. Mizuho analysts commented, "We just started our Spinraza webinar … here’s a link to the slides pdf Rating Neutral Previous Rating No Change Price (4/17) $274.05 Price Target $290.00 Previous Price Target No Change LINK to slides for our Spinraza webinar (for folks who prefer a pdf copy): CLICK HERE Link to join webinar (just started): CLICK HERE We intend to blast a replay of the webinar after we finish. PLEASE REFER TO PAGE 3 OF THIS REPORT FOR IMPORTANT DISCLOSURE AND ANALYST CERTIFICATION INFORMATION. Mizuho Securities USA LLC does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision." (4/18/2017)
• 4. Instinet analysts commented, "We are initiating on BIIB with a Buy rating and $345 target price. We recommend owning BIIB shares over the next 12 months given limited 2017 downside to revenue forecasts and potential Spinraza launch upside. We estimate that a successful Spinraza launch will drive above-consensus revenues of $11.6bn in 2017 and $12.2bn in 2018, despite flat MS-franchise growth that may be impacted by emerging competition (Ocrevus). We anticipate this return to growth will drive modest revenue multiple expansion and strong GAAP EPS growth - to $19.41 in 2017 and $21.56 in 2018, yielding upside to our $345 target price." (3/1/2017)
• 5. Jefferies Group LLC analysts commented, "This morning BIIB announced a settlement with FWP around Tecfidera IP. While we believe Street expectations were generally balanced going into the 3/17 decision (and we had assumed 50/50 prob. BIIB would be successful), commercial and some IPR risk remains, and recent focus has been more on Spinraza launch and Alzheimer’s, the terms look reasonable to us and help reduce an overhang." (1/18/2017)

Some companies that are related to Biogen include Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Abcam Plc (ABC), Anika Therapeutics (ANIK), Myovant Sciences Ltd (MYOV), Syros Pharmaceuticals (SYRS), ChemoCentryx (CCXI), Sinovac Biotech (SVA), Syndax Pharmaceuticals (SNDX), Peregrine Pharmaceuticals (PPHM), Fortress Biotech (FBIO), Kamada (KMDA), Mereo BioPharma Group PLC (MPH), MediWound (MDWD), Kadmon Holdings (KDMN), Cardiome Pharma Corporation (CRME), VIVUS (VVUS) and Strongbridge Biopharma PLC (SBBP).

Biogen's management team includes the folowing people:

• Stelios B. Papadopoulos Ph.D., Independent Chairman of the Board
• Michel Vounatsos, Chief Executive Officer, Director
• Gregory F. Covino, Interim Principal Financial Officer, Chief Accounting Officer, Vice President - Finance
• Kenneth A. Di Pietro, Executive Vice President - Human Resources
• Susan H. Alexander Esq., Executive Vice President, Chief Legal Officer and Corporate Secretary
• Michael D. Ehlers M.D., Ph.D., Executive Vice President, Head - Research and Development
• Adriana Karaboutis, Executive Vice President - Technology , Business Solutions and Corporate Affairs
• Jean-Paul Kress M.D., Executive Vice President, President - International and Head of Global Therapeutic Operations
• Paul McKenzie Ph.D., Executive Vice President - Pharmaceutical Operations & Technology
• Alfred W. Sandrock Jr., M.D., Ph.D., Executive Vice President - Neurology Discovery and Development and Chief Medical Officer

Biogen's stock is owned by many different of institutional and retail investors. Top institutional investors include Manning & Napier Advisors LLC (0.38%), Swedbank (0.27%), APG Asset Management N.V. (0.21%), Bank of Montreal Can (0.21%), Rockefeller Financial Services Inc. (0.12%) and Waverton Investment Management Ltd (0.10%). Company insiders that own Biogen stock include Adam Koppel, Adriana Karaboutis, Alexander J Denner, Alfred Sandrock, Brian S Posner, Caroline Dorsa, George A Scangos, Michel Vounatsos, Paul J Clancy, Robert W Pangia, Stelios Papadopoulos and Susan H Alexander. View Institutional Ownership Trends for Biogen.

Biogen's stock was sold by a variety of institutional investors in the last quarter, including Swedbank, DnB Asset Management AS, NN Investment Partners Holdings N.V., Nisa Investment Advisors LLC, Bedrijfstakpensioenfonds Voor DE Media PNO, Exxonmobil Investment Management Inc. TX, Meeder Asset Management Inc. and Creative Planning. Company insiders that have sold Biogen stock in the last year include Adriana Karaboutis, Alfred Sandrock, Brian S Posner, Caroline Dorsa, Paul J Clancy, Robert W Pangia and Susan H Alexander. View Insider Buying and Selling for Biogen.

Biogen's stock was bought by a variety of institutional investors in the last quarter, including Manning & Napier Advisors LLC, Bank of Montreal Can, Exane Asset Management, First Quadrant L P CA, Rockefeller Financial Services Inc., Mn Services Vermogensbeheer B.V., Factory Mutual Insurance Co. and Gateway Investment Advisers LLC. Company insiders that have bought Biogen stock in the last two years include Alexander J Denner, Michel Vounatsos and Stelios Papadopoulos. View Insider Buying and Selling for Biogen.

Shares of Biogen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Biogen stock can currently be purchased for approximately $282.92.